-+ 0.00%
-+ 0.00%
-+ 0.00%

Medivir secures US patent for fostrox-lenvatinib combination

PUBT·11/10/2026 07:35:42
Listen to the news
Medivir secures US patent for fostrox-lenvatinib combination
  • Medivir secured a US patent covering fostrox with lenvatinib for hepatocellular carcinoma and cancer metastases to the liver.
  • US protection and market exclusivity now extend to at least January 2044, nearly three years beyond the previously indicated April 2041.
  • A 1,001-day patent term adjustment compensates for administrative delays during examination.
  • The combination is being evaluated in the randomized phase 2 FLEX-HCC study.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medivir AB published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.